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Innovations in Clinical Research Design and Conduct   
in Psychiatry: Shifting to Pragmatic Approaches 
 
 
 
The classically structured clinical trial does not offer enough flexibility to make use of con-
tinuously emerging knowledge that is generated as the trial progresses. In this regard, there 
are consistent issues impeding effective psychiatric research, including limitations in efficien-
cy, difficulty demonstrating significant differences between treatment arms, poor external 
validity, and ethical constraints. For example, research in the field of psychiatry shows that it 
is growing increasingly more challenging to demonstrate superiority of interventions to pla-
cebo in part related to the increasing placebo response rates. Various design innovations and 
other tricks of the trade have surfaced to improve sensitivity towards detecting drug-placebo 
differences and reduce sources of bias in psychiatric research. Diverse strategies have been 
developed to address these obstacles and improve the outcomes of clinical research in psychi-
atry. The current review highlights many of these innovations and describes examples of their 
practical use, mainly focusing on the study design and conduct perspectives. In the study de-
sign issues, adaptive, equipoise stratified, sequential parallel and effectiveness design will be 
explored. The proper strategies for pragmatic and ethical conduction of clinical trials will be 
also discussed in-depth. 
 
KEY WORDS: Innovation, Strategies, Psychiatric research. 
 
Psychiatry Invest 2009;6:1-6  
David M. Marks1 
Thanaseelan J
1 
Chi-Un Pae
1,2 
1Department of Psychiatry and 
  Behavioral Sciences, Duke University, 
  Durham, NC, USA 
2Department of Psychiatry,   
The Catholic University of Korea 
College of Medicine, Seoul, Korea 
 
Received  November 27, 2008 
Accepted  December 10, 2008 
 
Correspondence 
David M. Marks, MD 
Department of Psychiatry and 
Behavioral Sciences, Duke University, 
2218 Elder St., Durham, NC 27704,   
USA 
Tel  +1-919-681-3840 
Fax  +1-919-620-0346 
E-mail  D.marks@duke.edu 
 
 
 
Introduction 
 
The scope of available interventions in the treatment of psychiatric disorders has
grown in recent decades in part through the diligent work of researchers investigat-
ing the usefulness of such interventions. Psychiatric research has become increasingly
innovative and sophisticated in order to optimize ethical conduct, maximize patient
safety, and increase the ability of potentially effective treatments to demonstrate su-
periority to placebo or noninferiority to standard of care interventions. Due to mount-
ing concerns that potentially effective pharmacotherapies are failing to outperform
placebo in clinical trials, strategies are evolving to increase efficiency, sensitivity, and
statistical power and to reduce bias. 
Additionally, emphasis is now being placed on the generalizability and external va-
lidity of psychiatric research, since patients encountered in clinical practice often do
not mirror populations of patients enrolled in industry-sponsored clinical trials. This 
emphasis has spawned large effectiveness trials designed to inform clinicians about 
the relative strengths of already marketed treatments in psychiatry. Innovations have
also been made in the ethical design and conduct of psychiatric research by allowing
greater flexibility in how patients are randomized to treatment. 
Modern study designs are adaptable to specific subject characteristics and to early
data collected over the course of the trial, and these innovations serve to expose pa-
tients to treatments that are more likely to be useful. The manner in which informed 
consent is collected is continuing to evolve in innovative ways, and this is particularly 
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important given the vulnerable nature of psychiatric pa-
tients. The current review introduces various innovations 
that have been employed in clinical research design and 
conduct and describes their intended benefits. 
 
Study Design Innovations 
 
Adaptive designs 
Adaptive design can be defined as a clinical study de-
sign that uses accumulating data to decide how to modify 
aspects of the study as it continues without undermining 
the validity and integrity of the trial.
1 In the opinion of 
some authors, adaptive design use in clinical research re-
fers to modifications that are incorporated into the study 
protocol and not developed on an ad-hoc basis to reme-
dy inadequate planning.
1 An example of adaptive design 
meeting this definition includes running patients through 
multiple interventions (i.e. treatment algorithms) based 
on their response to such interventions. These strategies 
individualize treatment via decision rules that recommend 
when and for whom the treatment should change.
2 
On the other hand, it has been suggested that adaptive 
designs include any adaptations or modifications made to 
the study or statistical procedures during the conduct of 
the trial, including those determined in amendments to 
clinical trial protocols.
3 Multiple examples of such adap-
tations have been described, including but not limited to 
1) sample Size Reestimation--adjustment of sample size 
to accommodate inaccurate prediction of effect size or 
variance  (thus preserving statistical power),
1 2 ) adap-
tive Treatment Allocation (and Adaptive Dose-Finding)-
alteration of the ratio of allocation to treatment arms bas-
ed on ethical grounds when an interim analysis reveals 
marked differences in effectiveness or tolerability between 
arms,
1,4 3 ) adaptive Hypothesis-change in the primary 
hypothesis of the study, which may include change in the 
primary outcome measure, shift from superiority hypoth-
esis to noninferiority hypothesis, interchanging the null 
and alternative hypotheses, and various other modifica-
tions of elements of the study hypothesis. 
Adaptive designs (whether a priori or ad hoc) offer the 
ethical advantage of better treatment of participants, the 
strategic advantage of improving probability of study suc-
cess, and the potential economic advantage of sparing re-
sources by reducing participant numbers. Yet, adaptive 
designs run the risk of increasing the chance of type I er-
ror, although authors have described multiple methods to 
combat this risk.
3 
There are inherent logistical issues in the use of some 
adaptive strategies, since data must be collected and ana-
lyzed rapidly and modifications resulting from this anal-
ysis must be quickly devised and approved by regulatory 
agencies. Overall, regulatory agencies have been slow to 
accept the application of adaptive designs in clinical re-
search. A PhRMA Working Group was formed in 2005 to 
evaluate the benefits and challenges of adaptive designs 
with the goal of increasing usage and regulatory accep-
tance of adaptive clinical trial designs.
1 
 
Equipoise stratified design 
Traditional randomized clinical trials are conducted in 
such a way that the treatment preferences of participants 
and investigators are ignored; randomization into two or 
more treatment arms occurs without the influence of cli-
nician or patient preference. 
This design seems to be the most scientifically pure, 
but in multiple arm clinical trials in human subjects it can 
unnaturally subject patients to treatments they do not pre-
fer and restrict clinical investigators from exercising judg-
ment to offer treatments they believe to be superior. La-
vori et al.
5 have developed a clinical trial design called 
the equipoise stratified design which allows some flexi-
bility in the randomization process by allowing partici-
pants and investigators to choose among groups (“e-stra-
tum”) containing multiple study arms. The clinician’s and 
patient’s preferences are identified in advance of assign-
ment to treatment, so that the random assignment can be 
made within strata defined by those preferences. For ex-
ample, in the recent Sequenced Treatment Alternatives 
to Relieve Depression (STAR*D) study,
6 patients who 
failed to respond adequately to the antidepressant citalo-
pram could choose to be assigned to one of two groups of 
interventions, “switch” or “augment”. Patients opting for 
the “switch” stratum were randomized equally to four 
arms consisting of three different antidepressants and cog-
nitive therapy. Patients opting for the “augment” stratum 
remained on citalopram and were randomized equally to 
three arms consisting of two different adjunctive agents 
and adjunctive cognitive therapy. This model has an ele-
ment of adaptive design in that preference for the “aug-
ment” stratum may have been preferentially chosen if pa-
tients had a partial response to citalopram.   
This issue illustrates the ethical advantage of the equi-
poise stratified design in that it allows individual patient 
experience to be considered prior to randomization, and 
this flexibility theoretically enhances generalizability and 
efficiency of enrollment. The equipoise stratified design 
is applicable only when treatment arms can be grouped 
into strata, which limits its use to a subset of clinical re-
search studies. 
 
Sequential parallel design 
High placebo response rates have limited the ability of 
psychiatric clinical trials to detect efficacy with pharma- 
 
 
 
 
DM Marks et al. 
www.psychiatryinvestigation.org 3 
cological interventions that ultimately have gained accep-
tance as effective treatments. Even when such interven-
tions lead to measured improvement, they risk nonsepara-
tion from placebo due to measured improvement in the 
placebo arms of clinical trials. 
Many of the research interventions discussed in the cur-
rent review are aimed at combating the trend of high pla-
cebo response rates. Included in these interventions is the 
sequential parallel design, a new study design proposed 
by Fava et al.
7 aimed at increasing the efficacy of double 
blind placebo controlled psychiatric clinical trials by re-
ducing placebo response rates and required sample size. 
The sequential parallel design combines data from a stand-
ard parallel placebo-controlled trial with data from a sec-
ond phase in which patients in the placebo arm who fail 
to improve are again randomized to study drug or placebo. 
Although such a design naturally extends the length of a 
clinical trial, it has been asserted that in antidepressant 
trials the duration of each phase can be shorter than a tra-
ditional parallel group trial. Other authors have expanded 
upon this design concept. The original design by Fava et 
al. proposed to allow responders in the first phase to con-
tinue on the drug in an open-label fashion during the sec-
ond phase.
7 Tamura et al.
8 proposed modifications to the 
sequential parallel design, including retaining patients on 
blinded medication throughout both phases of the trial with 
investigators blinded to the criteria for response and the 
exact timing of the initiation of the second phase.
8 These 
authors also propose to keep first phase study drug nonres-
ponders on the drug during the second phase in order to 
obtain additional tolerability data
8 in contrast to the sug-
gestion by Fava et al. to switch study drug nonresponders 
to placebo during the second phase.
7 
Statistical modeling has demonstrated that compared 
to traditional parallel design, the sequential parallel de-
sign allows reduction in sample size of 20-25% while re-
taining similar power.
8 This reduction leads to financial 
savings despite longer trial duration,
8 and we suspect that 
the reduced sample size would shorten total study length 
in most cases by reducing the enrollment period.   
 
Effectiveness studies 
Industry-sponsored registration trials in psychiatry tend 
to follow a standard design which involves short-term, 
double-blind, placebo-controlled, parallel group study of 
patients with acute episodes or exacerbations of chronic 
illness. Patients are excluded if they have substantial med-
ical comorbidity, and usually concomitant medication 
treatments are limited. Primary endpoints are typically 
investigator-scored efficacy measures (rating scales), and 
these trials are sometimes termed “efficacy studies”. Such 
research has been criticized in lacking external validity 
and it has been asserted that these efficacy studies do not 
provide sufficient information to clinicians in real-world 
settings.
9 
In contrast, some studies have been conducted with the 
intent of providing clinicians with useful practical data re-
garding the comparative effectiveness of marketed med-
ications. In particular, the Clinical Antipsychotic Trials 
of Intervention Effectiveness (CATIE) was aimed at de-
tecting differences in effectiveness and tolerability among 
available antipsychotic drugs.
10 CATIE compared several 
antipsychotics in a large sample of schizophrenic patients 
with relatively few exclusion criteria, and the primary 
outcome measure of “effectiveness” was “all cause dis-
continuation” in accordance with the desire to study a 
clinically-relevant and practical marker of efficacy and 
tolerability. Reasons for treatment discontinuation were 
compared such that clinicians now have a better under-
standing of how the various agents compare on efficacy, 
side effects, and overall treatment effectiveness in a com-
munity population of schizophrenics. Effectiveness stud-
ies are large, simple trials focusing on a small number of 
easily-measured endpoints and are therefore able to enroll 
large numbers of participants to answer “real-world” clin-
ical questions regarding the effectiveness of treatments.
9 
These studies aim to enroll typical community patients by 
having relatively lenient inclusion/exclusion criteria and 
concomitant medication restrictions, thus maximizing ex-
ternal validity. 
Table 1 summarizes the differences between traditional 
randomized, double-blind placebo-controlled clinical tri-
als (efficacy trials) and effectiveness trials. 
 
Study Conduct Innovations:  
Reducing Placebo Response Rates  
 
It is widely accepted that research on some psychi-
atric disorders is prone to high placebo response rates. 
Psychotic disorders and obsessive compulsive disorder 
(OCD) tend to have low placebo response rates in con-
trast to the high rates seen in studies of major depressive 
disorder (MDD), generalized anxiety disorder (GAD), 
and panic disorder.
11 Data indicate that placebo response 
rates in antidepressant trials exceed 30%,
11,12 and more 
than half of the clinical trials for approved antidepressants 
failed to show drug-placebo separation.
11,12 
The reasons for placebo response in psychiatric trials 
are numerous and beyond the scope of this review, but 
some of the main contributions to placebo response re-
late to interactions between research site staff and sub-
jects as well as rating scale bias. Rating scale bias occurs 
when investigators deliberately or unconsciously inflate 
the scores of efficacy measures at screen or randomiza- 
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tion to include subjects that might otherwise fall just be-
low the cutoff for inclusion in the trial. If scores are in-
flated to qualify marginal patients who enter the placebo 
arm, subsequent ratings will presumably show more ac-
curate ratings leading to false impression of improvement. 
Some innovative ways of addressing this tendency have 
been successfully implemented, including unlinking the 
inclusion criteria and the primary efficacy measure, and 
blinding the subjects and investigators to the time of ran-
domization. For example, the two registration trials lead-
ing to the United States Food and Drug Administration 
(US FDA) approval of quetiapine for the treatment of bi-
polar depression
13,14 and the two registration trials lead-
ing the US FDA approval of aripiprazole as adjunctive 
therapy in MDD
15,16 used the Montgomery Asberg De-
pression Rating Scale (MADRS) as the primary efficacy 
measure while using the Hamilton Rating Scale for De-
pression (HAM-D) to qualify patients at study screen and 
at randomization. This strategy was designed so that infla-
tion of rating scale scores (HAM-D) in order to enroll sub-
jects at screen and randomization would not lead to exag-
gerated scores on the primary efficacy measure (MADRS). 
Furthermore, some studies have adopted the design of bl-
inded time or randomization to combat subject expecta-
tions of improvement and the tendency of raters to in-
flate scores at the randomization visit. The aripiprazole 
registration trials referenced above blinded patients but 
not investigators to the time of randomization.
15,16 
Although most sponsors orient investigative site staff 
and provide good clinical practice training to the inves-
tigators at the beginning of every multi-center trial, the 
heterogeneity in the management of patients’ expectation 
among centers, and the occurrence of diagnostic misclas-
sification remains relevant.
17 In some centers, the interac-
tion between the investigators and the patients may favor 
the occurrence of strong placebo responses, affecting most 
of the subjects recruited at the center, and reducing the 
possibility of detecting any treatment effects.
18 
Some authors have gone so far as developing a method 
to determine which investigative sites yield high placebo 
response in a particular study and proposing that data 
from underperforming sites be dropped.
19 This premise 
is based on the notion that sites differ in their placebo re-
sponse rates, possibly as a function of how sites manage 
patient expectations. The determination of individual sites’ 
placebo response rates has been done retrospectively based 
on a signal detection approach,
20 and authors have pro-
posed a way to prospectively measure the response rates 
TABLE 2. Issues contributing to placebo response in psychiatric clinical trials
Source Potential  remedy 
Patient expectations of improvement  Patients should be educated that not everyone is expected to improve during study 
Nonspecific therapeutic effects of study visits  
(e.g. rapport with site staff) 
Investigators/raters should remain neutral and avoid providing “psychotherapy” 
 
Patients desire to please investigator  
(i.e. being a “good patient”) 
Patients should be instructed to report their symptoms accurately and educated that 
they are not disappointing anyone if they do not show improvement 
Spontaneous improvement/remission 
 
Avoid enrolling patients with episode/exacerbation induced by stressor; spontaneous 
improvement may occur as stressor is resolved or adaptation occurs 
Inflation of rating scale scores prior to randomization  Entry criteria should be unlinked to primary efficacy measure 
 
TABLE 1. A comparison between efficacy and effectiveness trials
Study characteristics  Efficacy (phase II/III) Effectiveness  (phase III/IV) 
Objective  Scientifically ideal conditions, confounding variables minimized  Comparison in “real world” patients 
Setting  Usually specialized research sites  Often community clinics 
Design Randomized  Flexible 
Sample size  Usually less than 200  200-1,000 
Inclusion/Exclusion criteria  Elaborate, rigid  Simple, Flexible 
Quality assurance  Elaborate  Minimal 
Control Placebo  Flexible 
Subgroup  Limited  Depending on sample size 
Outcome measures 
 
Symptomatic only (i.e., HAMD-17) 
 
Functional, economic, and service utilization 
(i.e., Discontinuation rate) 
Assessment Highly  elaborated  Moderately  elaborated 
Data collection  Highly elaborated  Simple 
Study management  Intensive  Minimal 
Generalizability Low  Intermediate 
Other intervention  Prohibited  Flexible 
HAMD: Hamilton Rating Scale for Depression 
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of additional patients treated in a double blind fashion 
with placebo outside the randomization sequence (“cali-
brator signal”).  
Table 2 summarizes the issues related to high placebo 
response in clinical trials. 
 
Innovations in Informed Consent 
 
Informed consent may be construed as one of the most 
fundamental ethical principles in human subjects research. 
Investigators bear a responsibility to ensure that subjects 
are able to voluntarily agree to research participation, and 
one of the primary roles of internal review boards (IRBs) 
is to ensure appropriate informed consent procedures. Yet, 
the leading cause of US FDA warning letters and 483 let-
ters to investigators is deficiency in informed consent, and 
research has demonstrated frequent misunderstanding by 
subjects in clinical research despite elaborate informed 
consent processes.
21,22 
The informed consent process has been conceptually 
divided into multiple steps which include 1) assessing the 
decision-making capacity or competence of the prospec-
tive research volunteer, 2) disclosing relevant information 
about the proposed research, 3) ensuring that the pro-
spective volunteer understands the information, 4) en-
suring that the prospective volunteer be positioned to make 
a voluntary choice, and 5) authorizing a decision by the 
prospective volunteer and, if affirmative, having him or 
her sign a consent form.
23,24 Various authors have sug-
gested that informed consent information be presented 
in multimedia format such as Powerpoint
25 or CD-ROM,
24 
although it has been noted that more elaborate presenta-
tions might unduly persuade potential subjects to partic-
ipate.
24 
In addition, questionnaires have successfully been ad-
ministered to improve the assessment of potential subjects’ 
understanding of what is involved in specific research 
protocols,
26 and a unique study improved the informed 
consent dialogue by embedding queries about the study 
process directly into the informed consent document.
25 
Such measures allow the investigator to more formally 
assess potential subjects’ understanding of the implica-
tions of research participation. Schwartz and Applebaum 
have advocated that research staff record informed con-
sent discussions for the purpose of quality control audit 
by the investigators and by regulatory agencies such as 
IRBs.
22 
 
Discussion 
 
Just as the science of medicine continuously evolves 
to provide better treatments, methodology evolves to en-
hance the sensitivity, efficiency, and moral integrity of 
clinical research. This evolution has various aims, which 
include improving the ability to determine whether spe-
cific interventions are of benefit, reducing the cost asso-
ciated with research, improving external validity, maxi-
mizing subject and clinician choice while preserving data 
integrity, exposing a greater number of subjects to the most 
effective and tolerable treatments, and safeguarding the 
safety and welfare of research subjects.   
Research in the field of psychiatry shows that it is grow-
ing increasingly more challenging to demonstrate superi-
ority of interventions to placebo in part related to the in-
creasing placebo response rates.
27 Various design innova-
tions and other tricks of the trade have surfaced to improve 
sensitivity towards detecting drug-placebo differences and 
reduce sources of bias in psychiatric research. Ultimately, 
it is an empirical question whether these many innova-
tions successfully improve efficiency and ability to detect 
differences in efficacy between various interventions or 
between interventions and placebo.   
Additionally, design innovations have enhanced the 
ethical conduct of research in several ways. Certain adap-
tive designs permit the use of treatment algorithms to 
tailor treatments to individual subject responses during a 
study, while other adaptive designs allow modifications 
to be made in protocol conduct based on early data col-
lected over the course of the study in such a way that more 
patients are exposed to treatments demonstrating safety 
and efficacy. Innovations in research ethics also include 
improvements in the way informed consent is acquired 
and monitored. This is particularly relevant in psychiatry, 
since many patients with mental illness may have reduced 
capacity to understand the risks, benefits, and alternatives 
related to study participation. It seems intuitive that the 
various innovations discussed are successful at improving 
the ethical conduct of psychiatric research, although in 
some ways this is an empirical question as well.   
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